A real world study evaluating and comparing long-term efficacy and safety of etrombopag and romiplostim in adult patients with chronic immune thrombocytopenia in clinical practice

Trial Profile

A real world study evaluating and comparing long-term efficacy and safety of etrombopag and romiplostim in adult patients with chronic immune thrombocytopenia in clinical practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Eltrombopag (Primary) ; Romiplostim (Primary)
  • Indications Immune thrombocytopenic purpura
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top